Engineered rAAV Capsid Peptide Insertions for CNS Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing recombinant adeno-associated viruses (rAAVs) face challenges in selectively and efficiently expressing in distinct cell-types, particularly in the central nervous system (CNS), upon systemic delivery.
Innovation Solution
Engineering rAAVs with peptide insertions in the capsid structure, selected through iterative rounds in non-human primates, to enhance transduction enrichment in the CNS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing rAAV serotypes are used for systemic delivery, then they can deliver to multiple tissues, but they fail to selectively transduce CNS cells with high efficiency
Solution Approach 1:
The patent applies local quality by introducing specific peptide sequences at defined positions within the AAV capsid structure. These localized modifications (e.g., peptides at positions 588-589, 452-458, or 640-645) create specific binding properties in particular regions of the capsid, enabling selective recognition of CNS cell surface receptors while maintaining overall capsid integrity and function.
Solution Approach 2:
The patent employs parameter changes by systematically varying amino acid sequences at specific capsid positions through iterative mutagenesis and selection. This involves changing the chemical properties, charge, and hydrophobicity of peptide regions to optimize binding affinity and specificity for CNS tropism, thereby transforming the capsid's tissue selectivity parameters.
2Productivity
If peptide insertions are engineered into the AAV capsid to enhance CNS transduction, then transduction efficiency in the CNS improves, but the capsid structure becomes more complex
Solution Approach 1:
The patent applies segmentation by dividing the capsid modification strategy into discrete, modular peptide insertions at specific positions rather than attempting global capsid redesign. This modular approach allows independent optimization of each peptide segment and simplifies the overall engineering process while achieving cumulative improvements in CNS transduction.
Solution Approach 2:
The patent employs partial action by introducing only the minimal necessary peptide changes at critical positions to achieve CNS enrichment, rather than comprehensively redesigning the entire capsid. This targeted approach achieves sufficient transduction improvement without unnecessary structural complexity.
3Manufacturing precision
If iterative selection is performed in non-human primates to optimize CNS transduction, then transduction enrichment in the CNS increases, but the development time and process complexity increase
Solution Approach 1:
The patent applies preliminary action by conducting iterative selections in non-human primates before final therapeutic application. This preliminary testing and optimization phase allows identification and elimination of ineffective variants early, establishing a refined library of high-performing capsids that are then ready for clinical use, thereby reducing overall development time despite the intensive initial selection process.
Data Source
AI summary
Described herein are compositions and kits comprising recombinant adeno-associated viruses (rAAVs) with increased viral transduction enrichment in the CNS. The rAAV compositions described herein encapsidate a transgene, such as a therapeutic nucleic acid. Gene therapy using the rAAVs is described. Also described are methods of treating CNS-related diseases and conditions.